Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.

Inclusion Criteria:

• Adults at the time of signing the Informed Consent Form (ICF)
• Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
• Diagnosed with T2DM

Exclusion Criteria:

• Diagnosed with other types of diabetes than T2DM
• History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
• Uncontrolled severe complications of diabetes